JPS5821623A - 抗原抗体複合体沈着疾患治療剤 - Google Patents
抗原抗体複合体沈着疾患治療剤Info
- Publication number
- JPS5821623A JPS5821623A JP56118928A JP11892881A JPS5821623A JP S5821623 A JPS5821623 A JP S5821623A JP 56118928 A JP56118928 A JP 56118928A JP 11892881 A JP11892881 A JP 11892881A JP S5821623 A JPS5821623 A JP S5821623A
- Authority
- JP
- Japan
- Prior art keywords
- gamma globulin
- antigen
- deposition
- treated
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 24
- 201000010099 disease Diseases 0.000 title claims description 23
- 230000008021 deposition Effects 0.000 title claims description 21
- 108010074605 gamma-Globulins Proteins 0.000 claims abstract description 61
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 238000011282 treatment Methods 0.000 abstract description 18
- 229940012957 plasmin Drugs 0.000 abstract description 16
- 206010018364 Glomerulonephritis Diseases 0.000 abstract description 14
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract description 9
- 108010044091 Globulins Proteins 0.000 abstract description 5
- 102000006395 Globulins Human genes 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 238000004090 dissolution Methods 0.000 abstract description 3
- 230000002255 enzymatic effect Effects 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 48
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 201000001474 proteinuria Diseases 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 238000011862 kidney biopsy Methods 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 6
- 108090000284 Pepsin A Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 229940111202 pepsin Drugs 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000005086 glomerual capillary Anatomy 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000031951 Primary immunodeficiency Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001780 adrenocortical effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940125698 hormone suppressant Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- -1 methyl thiolate Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010061415 Wrist deformity Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56118928A JPS5821623A (ja) | 1981-07-28 | 1981-07-28 | 抗原抗体複合体沈着疾患治療剤 |
| DE19823228007 DE3228007A1 (de) | 1981-07-28 | 1982-07-27 | Arzneimittel zur behandlung von systemischem lupus erythematodes und primaerer glomerulonephritis |
| DE3250068A DE3250068C2 (enrdf_load_stackoverflow) | 1981-07-28 | 1982-07-27 | |
| IT67956/82A IT1156482B (it) | 1981-07-28 | 1982-07-28 | Composizione per il trattamento del lupus eritematoso sistemico e glomerulonefrite primaria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56118928A JPS5821623A (ja) | 1981-07-28 | 1981-07-28 | 抗原抗体複合体沈着疾患治療剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57057875A Division JPS5821624A (ja) | 1982-04-06 | 1982-04-06 | 慢性関節リウマチの治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5821623A true JPS5821623A (ja) | 1983-02-08 |
| JPH0250884B2 JPH0250884B2 (enrdf_load_stackoverflow) | 1990-11-05 |
Family
ID=14748668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56118928A Granted JPS5821623A (ja) | 1981-07-28 | 1981-07-28 | 抗原抗体複合体沈着疾患治療剤 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS5821623A (enrdf_load_stackoverflow) |
| DE (2) | DE3228007A1 (enrdf_load_stackoverflow) |
| IT (1) | IT1156482B (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59101427A (ja) * | 1982-11-30 | 1984-06-12 | Teijin Ltd | 腎疾患治療剤 |
| JPS59190922A (ja) * | 1983-04-12 | 1984-10-29 | Green Cross Corp:The | 炎症治療予防剤 |
| JPS60185726A (ja) * | 1983-12-07 | 1985-09-21 | アンステイテユ メリユ− | 免疫調整医薬 |
| JPS61155335A (ja) * | 1984-12-28 | 1986-07-15 | Green Cross Corp:The | 免疫調節剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3763135A (en) * | 1971-11-08 | 1973-10-02 | Baxter Laboratories Inc | Gamma globulin production from cohn fraction iii using polyethylene glycol |
| DE2560155C2 (de) * | 1974-03-08 | 1984-04-26 | Teijin Ltd., Osaka | Humanimmunglobulin-Derivat |
| CA1064396A (en) * | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| US4165370A (en) * | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
| US4124576A (en) * | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
-
1981
- 1981-07-28 JP JP56118928A patent/JPS5821623A/ja active Granted
-
1982
- 1982-07-27 DE DE19823228007 patent/DE3228007A1/de active Granted
- 1982-07-27 DE DE3250068A patent/DE3250068C2/de not_active Expired - Fee Related
- 1982-07-28 IT IT67956/82A patent/IT1156482B/it active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59101427A (ja) * | 1982-11-30 | 1984-06-12 | Teijin Ltd | 腎疾患治療剤 |
| JPS59190922A (ja) * | 1983-04-12 | 1984-10-29 | Green Cross Corp:The | 炎症治療予防剤 |
| JPS60185726A (ja) * | 1983-12-07 | 1985-09-21 | アンステイテユ メリユ− | 免疫調整医薬 |
| JPS61155335A (ja) * | 1984-12-28 | 1986-07-15 | Green Cross Corp:The | 免疫調節剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3228007A1 (de) | 1983-02-17 |
| DE3228007C2 (enrdf_load_stackoverflow) | 1992-01-30 |
| IT8267956A0 (it) | 1982-07-28 |
| JPH0250884B2 (enrdf_load_stackoverflow) | 1990-11-05 |
| DE3250068C2 (enrdf_load_stackoverflow) | 1992-08-06 |
| IT1156482B (it) | 1987-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spitler et al. | Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin | |
| Thompson et al. | Drug‐induced lichen planus | |
| US6074642A (en) | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis | |
| Lawrence et al. | Two patterns of skin ulceration induced by methotrexate in patients with psoriasis | |
| DE3855869T2 (de) | Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern | |
| Goodfellow et al. | Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen‐induced arthritis | |
| Gilliam et al. | Fibrinolytic therapy for vasculitis of atrophie blanche | |
| MXPA98000760A (en) | Methods for the treatment of asthma allergy | |
| BR112021008778A2 (pt) | Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn | |
| JP2730889B2 (ja) | 単クローン性抗体療法 | |
| Kelley et al. | The nephrotic syndrome in children: I. Clinical response to nitrogen mustard therapy | |
| Kürschner et al. | IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenicity, and in vivo activity | |
| Walsh et al. | Effects of cetirizine on human eosinophil and neutrophil activation in vitro | |
| Germain et al. | Pulmonary hemorrhage and acute renal failure in a patient with mixed connective tissue disease | |
| Avasthi et al. | Benign monoclonal gammaglobulinemia and glomerulonephritis | |
| KR100533399B1 (ko) | 경구투여용제제 | |
| Tani et al. | Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models | |
| JPS5821623A (ja) | 抗原抗体複合体沈着疾患治療剤 | |
| Bao et al. | Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes | |
| CA2091134C (en) | Therapeutic agent for threatened abortion | |
| CA1341425C (en) | Antibodies to angiogenin: immunotherapeutic agents | |
| La Via et al. | Studies on Fc receptor function: I. IgG-mediated inhibition of B lymphocyte activation by T-dependent and T-independent antigens | |
| US5520914A (en) | Antibodies to angiogenin: immunotherapeutic agents | |
| US4465670A (en) | Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor | |
| JPH0251405B2 (enrdf_load_stackoverflow) |